The Vexing Problem of HFpEF Therapeutics
Publication
, Journal Article
Litwin, SE; Zile, MR
Published in: JACC: Heart Failure
May 2021
Duke Scholars
Published In
JACC: Heart Failure
DOI
ISSN
2213-1779
Publication Date
May 2021
Volume
9
Issue
5
Start / End Page
371 / 373
Publisher
Elsevier BV
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Litwin, S. E., & Zile, M. R. (2021). The Vexing Problem of HFpEF Therapeutics. JACC: Heart Failure, 9(5), 371–373. https://doi.org/10.1016/j.jchf.2021.02.005
Litwin, Sheldon E., and Michael R. Zile. “The Vexing Problem of HFpEF Therapeutics.” JACC: Heart Failure 9, no. 5 (May 2021): 371–73. https://doi.org/10.1016/j.jchf.2021.02.005.
Litwin SE, Zile MR. The Vexing Problem of HFpEF Therapeutics. JACC: Heart Failure. 2021 May;9(5):371–3.
Litwin, Sheldon E., and Michael R. Zile. “The Vexing Problem of HFpEF Therapeutics.” JACC: Heart Failure, vol. 9, no. 5, Elsevier BV, May 2021, pp. 371–73. Crossref, doi:10.1016/j.jchf.2021.02.005.
Litwin SE, Zile MR. The Vexing Problem of HFpEF Therapeutics. JACC: Heart Failure. Elsevier BV; 2021 May;9(5):371–373.
Published In
JACC: Heart Failure
DOI
ISSN
2213-1779
Publication Date
May 2021
Volume
9
Issue
5
Start / End Page
371 / 373
Publisher
Elsevier BV
Related Subject Headings
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology